lucky jili slot 777 real money

It's always a great time to invest in quality businesses that can prime your portfolio for long-term growth. It's important to be selective with the companies that you add to your portfolio and ensure that you only put cash into investments that align with your overall investment priorities, risk tolerance, and long-term goals. You should also only put cash to work that you can leave in your portfolio for a few years, not funds that you might soon need for bills or other financial obligations. On that note, if you're looking for top-notch growth stocks to buy right now and have $1,000 available to invest, here are two names to consider. 1. Eli Lilly Eli Lilly ( LLY -0.26% ) has been the darling of pharmaceutical stocks in the last 12 to 18 months, with shares rocketing upward as the popularity of its GLP-1 drugs has propelled revenue and earnings. Bear in mind, this is one of the oldest healthcare companies in the world, with a lineup of top-selling drugs across a range of disease categories that target everything from various cancers and cardiovascular ailments to endocrine disorders and neurological conditions. In the first nine months of 2024 alone, shares roared upward to the tune of about 62%. After the company reported its earnings for the third quarter of 2024, shares took a double-digit nosedive as investors responded negatively to a few key points, including a slight pullback in full-year guidance. The company also reported financial figures that were slightly below what Wall Street had expected. In terms of its full-year guidance, where Eli Lilly was targeting revenue for the 12-month period in the $45.4 billion to $46.6 billion range, the company is now projecting that it will deliver in the ballpark of $45.4 billion to $46 billion. Its Q3 revenue was around $800 million below what analysts had aimed for. That being said, a closer look is warranted, and the long-term outlook for this business is anything but dismal. Revenue in Q3 2024 rose 20% year over year to $11.4 billion. The company sold rights for its olanzapine portfolio in Q3, featuring products used to treat ailments such as schizophrenia and bipolar disorder. If you exclude revenue from this portfolio, Eli Lilly's top line actually jumped 42% on a year-over-year basis, which is a bit more than the 36% growth it reported in the second quarter. The company also reported net income of approximately $970 million in Q3. Tirzepatide, which is the main active ingredient in its top-selling drugs Mounjaro (for diabetes) and Zepbound (for weight loss), is being studied by Eli Lilly across multiple other disease areas. For example, positive phase 3 trial data from a 176-week study of tirzepatide demonstrated a 94% reduction in the risk of developing type 2 diabetes in adults with pre-diabetes who are obese or overweight. Another first-of-its-kind study initiated by Eli Lilly has been studying tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In this phase 3 trial, tirzepatide reduced heart failure symptoms and physical limitations while lowering the risk of worsening heart failure events by 38%. Risk of hospitalization for heart failure was also reduced by 56% in trial patients taking tirzepatide. In short, the future revenue and profit opportunities from tirzepatide may be in the very early innings. In Q3, sales of Mounjaro rose more than 121% year over year to $3.1 billion, while Zepbound (which was just approved last November) raked in $1.3 billion in sales. This was despite negative effects for both drugs cited by Eli Lilly that were caused by inventory decreases in the wholesaler channel. Blockbuster cancer drug Verzenio generated $1.37 billion in sales in the quarter, up 32% from one year ago, while sales of autoimmune disease drug Taltz jumped 18% to $879.6 million. While investors appear to be particularly reactionary in the current environment, that can present an opportunity for those with a sufficient buy-and-hold horizon to take a slice of the action. While Eli Lilly doesn't trade at a cheap valuation by any means, its annual dividend of $5.20 and steady increase to its payout can augment total investor returns. Investors who want to become part-owner in a top healthcare business with a steady global footprint may be remiss to overlook this quality stock. 2. Monday.com Monday.com ( MNDY 3.02% ) is a low-code and no-code platform that helps organizations build the work management tools and software applications they need to ensure business operations run smoothly. The company derives its revenue from monthly or annual subscription agreements that it enters into with customers who use its cloud-based platform. Monday.com's software enables everything from project management and collaboration to helping keep tools and files in a single location for easy access. Clients with little to no coding experience can leverage its platform to develop customized workflow apps featuring boards, charts, and other important automation solutions. Companies like Canva, Lionsgate , and Coca-Cola are just a handful of the big names on Monday.com's client roster. Investors have been particularly optimistic about Monday.com's performance recently, with shares skyrocketing to the tune of about 50% over the trailing 12-month period. As always, share price is never a reason to buy (or sell) a stock. You need to look at the underlying business, its drivers and detractors of growth, its financial performance, its industry, and its long-term growth runway to gain a clear picture of whether it's a wise fit for your portfolio. In the case of Monday.com, the company has only been in business since 2012, so it's still in the relatively early stages of its potential growth story. Management estimates that the company operates in a large and growing total addressable market, which could hit a valuation of $150 billion by the year 2026. The diverse range of solutions that Monday.com's platform offers allows it to target various segments of its overall market opportunity, including the $30 billion customer relationship management (CRM) software market. From a financial perspective, Monday.com is doing quite well. Its third-quarter revenue rose 33% from the year-ago period to $251 million, and the company officially surpassed the $1 billion annual recurring revenue (ARR) mark. Its overall net dollar retention rate (NRR) increased to 111%, while NRR for customers with more than $100,000 in ARR was 115%. The number of paid customers with more than $100,000 in ARR jumped 44% from one year ago. Meanwhile, the company's second-largest customer, which is an unnamed international technology company, more than doubled its seat count to 60,000 from 25,000. Although Monday.com is not profitable on the basis of generally accepted accounting principles ( GAAP ), cash flow is another core profitability metric to consider. From a free cash flow perspective, the company raked in $82.4 million of free cash flow, while net cash provided by operating activities was $86.6 million in Q3. While investors may need a certain level of risk tolerance to invest in software stocks, this resilient business looks like a compelling addition to a well-diversified portfolio.Learning Management Systems Market Revolutionizing Education with Digital Learning PlatformsNC State had its lead trimmed to 54-46 midway through the third quarter before James scored five straight points to begin a 13-2 run that ended in a 19-point lead. Quigley took over in the fourth, making three 3-pointers and scoring 15 points. Coastal Carolina missed 11 of 13 shots spanning the third-quarter break as NC State pulled away. Madison Hayes added 18 points on 7-of-10 shooting for NC State (3-2). James has scored 20-plus in three straight games. The Wolfpack shot 50% from the field, including 11 of 29 from 3-point range. Hayes made her third 3-pointer with 1:12 left in the first half to give NC State a 47-32 lead. Coastal Carolina's Savannah Brooks just beat the halftime buzzer with a basket to give her 17 points and pull within 47-36. Brooks scored 14 of Coastal Carolina’s opening 26 points and she finished the game with 25. Alancia Ramsey added 13 points for Coastal Carolina (4-1), which was picked to finish ninth in the Sun Belt Conference. The Wolfpack travel to the Bahamas to play in the Pink Flamingo Championship against Southern on Monday. Coastal Carolina battles Division II Coker on Wednesday. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketball

Boston College puts it all together in 41-21 victory over North Carolina, winning a place in a bowl gameNEW DELHI, Dec 28 : Union Minister of State (Independent Charge) for Science and Technology, Minister of State (Independent Charge) for Earth Sciences, MoS, PMO, Department of Atomic Energy, Department of Space, Personnel, Public Grievances and Pensions, Dr Jitendra Singh informed here today that (Indian Space Research Organisation) ISRO’s year-end mission scheduled for 30th December is going to be a historic one as it will seek the rare feat of docking or merging or joining together two satellites in Space. The project has been named “Space Docking Experiment” (SpaDeX), he said. The whole nation looks forward with bated breath as ISRO is set to achieve a significant milestone in Space technology, said the Minister in the Department of Space. In an exclusive media interview, Dr Jitendra Singh elaborated that the upcoming SpaDeX mission aims to dock two satellites in Space, a challenge only mastered by a few countries. This ambitious project will take place on December 30, 2024, under the Space Docking Experiment (SpaDeX) and the indigenous technology used for this mission is called the “Bharatiya Docking System”. “SpaDEX” will mark a milestone, showcasing India’s expertise in spacecraft docking technology. This mission, said Dr Jitendra Singh, will mark India’s entry into the exclusive league of nations capable of mastering space docking. A unique approach, the PSLV rocket, will launch two satellites equipped with the ‘Bhartiya Docking System’ to demonstrate this complex feat, he added. The success of this mission is vital for India’s future space ambitions, said the Minister. Docking technology is key for long-term missions like “Chandrayaan-4” and the planned Indian space station. It is also crucial for the eventual manned “Gaganyaan” mission. In the near vacuum of Space, the handout said, ISRO will attempt to dock two satellites orbiting at speeds of 28,800 km/h. This is a challenging task, as both satellites must be carefully manoeuvred to reduce their relative velocities to a mere 0.036 km/h. The two satellites, designated ‘Chaser’ and ‘Target’, will merge to form a single unit in Space. ISRO’s achievement will place India among the world’s space leaders, marking a step towards greater space exploration and innovation. SpaDeX is a significant milestone that paves the way for more complex space missions in the coming years. ISRO’s SpaDEX mission is set to launch on Dec 30, 2024, will demonstrate India’s Spacecraft Docking technology, marking a crucial step in space exploration and satellite servicing capabilities. India is preparing for a key step in space exploration. ISRO will launch the Space Docking Experiment (SpaDEX) on December 30, 2024. The mission will use PSLV-C60, lifting off at 21:58 IST from Sriharikota. SpaDEX marks a milestone, showcasing India’s expertise in spacecraft docking technology. SpaDEX will deploy two identical satellites, SDX01 and SDX02. Each satellite weighs around 220 kilograms and will orbit 470 km above Earth. Key objectives include Performing precision rendezvous and docking manoeuvres, Validating power transfer between docked spacecraft and Operating payloads post-undocking, with a two-year lifespan. This mission is essential for future endeavours, including satellite servicing and building India’s space station, Bharatiya Antriksh Station. SpaDEX will also use PSLV’s fourth stage, POEM-4, for experiments. The stage will carry 24 payloads from academic institutions and startups. These experiments will utilise the microgravity environment in orbit. SpaDEX will demonstrate docking and undocking capabilities between satellites. This includes transferring power and operating scientific payloads. The mission will simulate a sequence of manoeuvres, starting with a far rendezvous phase at 20 km and ending with docking at 3 metres. This capability is vital for India’s lunar and interplanetary missions. Docking technology enables multi-launch missions and supports future human spaceflight. Only the US, Russia, and China have mastered such advancements so far.